Hepatitis B virus serum profiles in injection drug users and rates of immunization over time in Barcelona: 1987-2006

Drug and Alcohol Dependence

Volumn 110, Issue 3, 2010, Pages 234-239

  Rivas, Inmaculada ^a,b   Martinez, Elisenda ^b   Sanvisens, Arantza ^b   Bolao, Ferran ^c   Tor, Jordi ^b   Torrens, Marta ^d   Pujol, Ramon ^c   Fuster, Daniel ^b   Rey Joly, Celestino ^b   Muñoz, Álvaro ^e   Muga, Roberto ^b  

^a Municipal Centre for Substance Abuse Treatment (Centro Delta)   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Hepatitis B; Injection drug users; Vaccine

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADULT; AGE DISTRIBUTION; ALCOHOLISM; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG DETOXIFICATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; INNATE IMMUNITY; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; SEROPREVALENCE; SPAIN; TREND STUDY; VIRUS IMMUNITY; VIRUS LOAD; COMPLICATION; CROSS-SECTIONAL STUDY; ISOLATION AND PURIFICATION; PREVALENCE; SUBSTANCE ABUSE; TIME; VIREMIA; VIROLOGY;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; MALE; PREVALENCE; SPAIN; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; VIREMIA;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 77954656312     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.03.005     Document Type: Article

References (39)

1. Alter M.J. Epidemiology and prevention of hepatitis B. Semin. Liver Dis. 2003, 23:39-46.
2. Amesty S., Ompad D.C., Galea S., Fuller C.M., Wu Y., Koblin B., Vlahov D. Prevalence and correlates of previous hepatitis B vaccination and infection among young drug-users in New York city. J. Community Health 2008, 33:139-148.
3. Bailey C.L., Smith V., Sands M. Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults. Int. J. Infect. Dis. 2008, 12:e77-e83.
4. Baral S., Sherman S.G., Millson P., Beyrer C. Vaccine immunogenicity in injecting drug users: a systematic review. Lancet Infect. Dis. 2007, 7:667-674.
5. Bonanni P., Pesavento G., Boccalini S., Bechini A. Perspectives of public health: present and foreseen impact of vaccination on the epidemiology of hepatitis B. J. Hepatol. 2003, 39(Suppl. (1)):S224-S229.
6. Brook G. Prevention of viral hepatitis in HIV co-infection. J. Hepatol. 2006, 44:S104-S107.
7. Burt R.D., Hagan H., Garfein R.S., Sabin K., Weinbaum C., Thiede H. Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18-30 years, 1994-2004. J. Urban Health 2007, 84:436-454.
8. Campbell J.V., Garfein R.S., Thiede H., Hagan H., Ouellet L.J., Golub E.T., Hudson S.M., Ompad D.C., Weinbaum C. Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users. Drug Alcohol Depend. 2007, 91(Suppl. (1)):S64-S72. DUIT Study Team.
9. Centers for Disease Control and Prevention (CDC) Hepatitis Surveillance Report 2006, Centers for Disease Control and Prevention, Atlanta GA.
10. de la Fuente L., Bravo M.J., Barrio G., Parras F., Suarez M., Rodes A., Noguer I. Lessons from the history of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic among Spanish drug injectors. Clin. Infect. Dis. 2003, 37(Suppl. (5)):S410-S415.
11. de la Fuente L., Brugal M.T., Domingo-Salvany A., Bravo M.J., Neira-Leon M., Barrio G. More than thirty years of illicit drugs in Spain: a bitter story with some messages for the future. Rev. Esp. Salud Publica 2006, 80:505-520.
12. de la Fuente L., Toro C., Brugal M.T., Vallejo F., Soriano V., Barrio G., Ballesta R., Bravo M.J. Poor validity of self-reported HBV vaccination among young heroin users in Spain supports the policy " don't ask, draw a blood sample, vaccinate and try to schedule another visit" J. Clin. Virol. 2007, 38:87-90. Project Itinere Group.
13. de la Torre J., Esteban R. Implementing universal vaccination programmes: Spain. Vaccine 1995, 13(Suppl. (1)):S72-S74.
14. Delgado-Iribarren A., Calvo M., Perez A., del Alamo M., Cercenado S. Intravenous drug users serologic control: what may be prevented?. Enferm. Infecc. Microbiol. Clin. 2000, 18:2-5.
15. Dienstag J.L. Hepatitis B virus infection. N. Engl. J. Med. 2008, 359:1486-1500.
16. Ganem D., Prince A.M. Hepatitis B virus infection-natural history and clinical consequences. N. Engl. J. Med. 2004, 350:1118-1129.
17. Garfein R.S., Vlahov D., Galai N., Doherty M.C., Nelson K.E. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am. J. Public Health 1996, 86:655-661.
18. Goldstein S.T., Alter M.J., Williams I.T., Moyer L.A., Judson F.N., Mottram K., Fleenor M., Ryder P.L., Margolis H.S. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J. Infect. Dis. 2002, 185:713-719.
19. Hope V.D., Ncube F., Hickman M., Judd A., Parry J.V. Hepatitis B vaccine uptake among injecting drug users in England 1998 to 2004: is the prison vaccination programme driving recent improvements?. J. Viral Hepat. 2007, 14:653-660.
20. Hutchinson S.J., Wadd S., Taylor A., Bird S.M., Mitchell A., Morrison D.S., Ahmed S., Goldberg D.J. Sudden rise in uptake of hepatitis B vaccination among injecting drug users associated with a universal vaccine programme in prisons. Vaccine 2004, 23:210-214.
21. Judd A., Hickman M., Hope V.D., Sutton A.J., Stimson G.V., Ramsay M.E., Gill O.N., Parry J.V. Twenty years of selective hepatitis B vaccination: is hepatitis B declining among injecting drug users in England and Wales?. J. Viral Hepat. 2007, 14:584-591.
22. Kottiri B.J., Friedman S.R., Euler G.L., Flom P.L., Sandoval M., Neaigus A., Des Jarlais D.C., Zenilman J.M. A community-based study of hepatitis B infection and immunization among young adults in a high-drug-use neighbourhood in New York city. J. Urban Health 2005, 82:479-487.
23. Kuo I., Mudrick D.W., Strathdee S.A., Thomas D.L., Sherman S.G. Poor validity of self-reported hepatitis B virus infection and vaccination status among young drug users. Clin. Infect. Dis. 2004, 38:587-590.
24. Kuo I., Sherman S.G., Thomas D.L., Strathdee S.A. Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection. Drug Alcohol Depend. 2004, 73:69-78.
25. Laurence J.C. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am. J. Med. 2005, 118(Suppl. (10A)):75S-83S.
26. Lee W.M. Hepatitis B virus infection. N. Engl. J. Med. 1997, 337:1733-1745.
27. Levine O.S., Vlahov D., Koehler J., Cohn S., Spronk A.M., Nelson K.E. Seroepidemiology of hepatitis B virus in a population of injecting drug users. Association with drug injection patterns. Am. J. Epidemiol. 1995, 142:331-341.
28. Lum P.J., Hahn J.A., Shafer K.P., Evans J.L., Davidson P.J., Stein E., Moss A.R. Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. J. Viral Hepat. 2008, 15:229-236.
29. Mast E.E., Weinbaum C.M., Fiore A.E., Alter M.J., Bell B.P., Finelli L., Rodewald L.E., Douglas J.M., Janssen R.S., Ward J.W. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR Recomm. Rep. 2006, 55:1-33. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC), quiz CE1-4.
30. Muga R., Roca J., Egea J.M., Tor J., Sirera G., Rey-Joly C., Munoz A. Mortality of HIV-positive and HIV-negative heroin abusers as a function of duration of injecting drug use. J. Acquir. Immune Defic. Syndr. 2000, 23:332-338.
31. Namgyal P. Impact of hepatitis B immunization, Europe and worldwide. J. Hepatol. 2003, 39(Suppl. (1)):S77-S82.
32. Quaglio G., Talamini G., Lugoboni F., Lechi A., Venturini L., Jarlais D.C., Mezzelani P. Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response. Addiction 2002, 97:985-992. Gruppo Intersert di Collaborazione Scientifica.
33. Ramirez-Jonville A. Drug addiction: harm reduction policies in France and Spain. Presse Med. 2006, 35:1151-1161.
34. Rodriguez C., Castilla J., del Romero J., Lillo A., Puig M.E., Garcia S. Prevalence of hepatitis B virus infection and needs of vaccination in high risk populations. Med. Clin. (Barc) 2003, 121:697-699.
35. Salleras L., Bruguera M., Taberner J.L., Dominguez A., Batalla J., Buti M., Plans P., Navas E., Costa J., Vidal J., Prats R., Esteban R. Effectiveness of the mass antihepatitis B program in preadolescents in Catalonia. Med. Clin. (Barc) 2003, 121(Suppl. (1)):79-82.
36. Tseng F.C., O'Brien T.R., Zhang M., Kral A.H., Ortiz-Conde B.A., Lorvick J., Busch M.P., Edlin B.R. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology 2007, 46:666-671.
37. Vallejo F., Toro C., de la Fuente L., Brugal M.T., Barrio G., Soriano V., Ballesta R., Bravo M.J. Hepatitis B vaccination: an unmet challenge in the era of harm reduction programs. J. Subst. Abuse Treat. 2008, 34:398-406. Project Itinere Group.
38. Wasley A., Miller J.T., Finelli L. Surveillance for acute viral hepatitis-United States, 2005. MMWR Surveill. Summ. 2007, 56:1-24. Centers for Disease Control and Prevention (CDC).
39. Wiedmann M., Liebert U.G., Oesen U., Porst H., Wiese M., Schroeder S., Halm U., Mossner J., Berr F. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 2000, 31:230-234.